What encompasses a pharmacological approach to target validation?

Question

BlackTom AI · Accepted Answer

Pharmacological validation involves using small molecules or antibodies to modulate a protein’s activity and then observing the resulting biochemical or phenotypic effects, so the correct choice is c.

1) Relevant knowledge points and concepts
- Target validation: demonstrating that modulation of a biological target produces the desired effect on disease-relevant pathways or phenotypes.
- Pharmacological approach: uses chemical tools (small‑molecule inhibitors/activators) or biologics (monoclonal antibodies) to alter target activity acutely and reversibly.
- Complementary considerations: specificity, dose–response, temporal control, use of orthogonal chemotypes, and in vitro/in vivo confirmation.

2) Step‑by‑step reasoning process
- Choose a pharmacological agent that binds/modulates the target (e.g., inhibitor, agonist, antibody).
- Test in biochemical assays to confirm on‑target engagement (binding, enzymatic inhibition).
- Move to cellular assays to observe downstream readouts (signaling, viability, morphology) and establish dose–response and time course.
- Use controls: inactive analogs, known off‑target inhibitors, and rescue experiments (e.g., overexpress target or use a resistant mutant) to confirm effects are target‑mediated.
- Translate to animal models to assess disease‑relevant efficacy while monitoring pharmacokinetics/pharmacodynamics.
- Use multiple chemotypes or antibodies to reduce the chance that observed effects are due to off‑target activity.

3) Calculations
- Not applicable here; pharmacological validation relies on experimental design, dose–response curves, and statistical analysis rather than a specific numeric calculation in this question.

4) Why the correct answer is correct
- Option c explicitly states using small molecules or antibodies to modulate the target and observe effects, which is the definition and practice of pharmacological target validation.

5) Why other options are incorrect
- a (genetic knockouts) describes a genetic approach (loss‑of‑function), not a pharmacological approach.
- b (assessing drug toxicity) is part of preclinical safety profiling, not target validation per se.
- d (identifying protein structure) is structural biology useful for drug design but does not by itself demonstrate that modulating the target alters disease biology.

6) Conclusion
- Therefore, option c is correct: Using small molecules or antibodies to modulate the target and observe effects, matching the provided answer.

What encompasses a pharmacological approach to target validation?单项选择题

类似问题

What would be the most suitable approach in target validation if you have a disease model and a diverse library of compounds?如果你拥有疾病模型和多样化的化合物库，靶点验证中最合适的方法是什么？

What is a reverse approach in the context of target validation?在目标验证的背景下，什么是反向方法？

What is a forward approach in the context of target validation?在目标验证的背景下，什么是前瞻性方法？

Is it important to use diverse techniques to validate targets?

What encompasses a pharmacological approach to target validation?什么样的药理学方法用于靶点验证？

Is it important to use diverse techniques to validate targets?使用多样化技术验证靶点重要吗？

Where does target validation fit into the drug discovery pipeline?靶点验证在药物发现流程中处于什么位置？

Is it important to use diverse techniques to validate targets?

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单